ProKidney price target raised to $9 from $6 at Citi
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Why Nubank (NU) Stock Is Trading Up Today
What Happened? Shares of digital banking platform Nubank (NYSE:NU) jumped 3.7% in the afternoon session after receiving a rare double upgrade from Citi, which significantly boosted its rating on the stock. The firm issued a rare double upgrade, shifting its rating on the stock from 'Sell' all the way to 'Buy' and doubling its price target to $18 from $9. This dramatic shift in perspective follows Nu Holdings' strong second-quarter performance, which showed robust profit and revenue growth. Citi cited the potential for an earnings boost as a key reason for the change. After the initial pop the shares cooled down to $13.65, up 3.9% from previous close. Is now the time to buy Nubank? Access our full analysis report here, it's free. What Is The Market Telling Us Nubank's shares are very volatile and have had 20 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Nubank is up 28.4% since the beginning of the year, but at $13.65 per share, it is still trading 14.1% below its 52-week high of $15.89 from November 2024. Investors who bought $1,000 worth of Nubank's shares at the IPO in December 2021 would now be looking at an investment worth $1,321. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
25 minutes ago
- Business Insider
QQQ ETF News, 8/20/2025
How is QQQ stock faring? The Invesco QQQ ETF has declined 0.79% over the past five days, but is up 13.2% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, QQQ is a Moderate Buy. The Street's average price target of $638.41 for the QQQ ETF implies an upside potential of about 12.1%. Currently, QQQ's five holdings with the highest upside potential are Strategy (MSTR), Charter Communications (CHTR), Atlassian Corporation (TEAM), Trade Desk (TTD), and Lululemon Athletica (LULU). (PLTR), Tesla (TSLA), Intel (INTC), and Fastenal (FAST).
Yahoo
an hour ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
